Our Company
About Us
Our Team
Board of Directors
Scientific Advisory Board
Contact Us
Our Strategy
Scientific Platform
Therapeutic Areas
Manufacturing
Research & Development
Pipeline
Clinical Trials
Posters & Publications
Patients & Families
Investors & Media
Overview
News Releases
Events & Presentations
Stock Information
Corporate Governance
Financial Information
Investor Resources
Join Our Team
AAV5-
RPGR
Gene Therapy for
RPGR
-Associated X-Linked Retinitis Pigmentosa: 12-month Results From a Phase 1/2 Clinical Trial.